WHO Rapid Communication - August 2018
WHO has recently published a Rapid Communication on key changes to treatment of multi-drug and rifampicin-resistant TB (MDR/RR-TB) as a prelude to the formal guidance – the document is available here: http://www.who.int/tb/publications/2018/rapid_communications_MDR/en/ and the final guideline will not be issued until later this year.
As such, the communications does not notify you of decisions that have been taken or immediate changes in practice that are to be implemented, but of advice which health systems now need to use to plan for future changes in implementation.
BTS has produced information to assist those managing patients with MDR/RR-TB in the light of the new guideline - read more:
|Tuberculosis - Clinical diagnosis and management of tuberculosis, and measures for its prevention and control||January 2016||
Tuberculosis - NICE guideline NG33 covers preventing, identifying and managing latent and active tuberculosis (TB) in children, young people and adults.
|Defining a model for a Gold Standards for a TB MDT Group and associated networks||March 2014||
This document has been prepared in order to provide advice and input from the British Thoracic Society to the NHS, Public Health England (PHE) and other national stake-holders to strengthen TB control throughout the UK and inform the current PHE consultation on a national TB strategy. It is intended as a resource to guide the development of local and regional multidisciplinary networks to enhance and facilitate the coordination of care for TB.
|BTS Clinical Statement Management of Multidrug-Resistant Tuberculosis (MDRTB)||November 2016||
BTS Clinical Statement on the Management of Multidrug-Resistant Tuberculosis (MDRTB)